Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment

被引：128

作者：

Fleming, CA ^{[1
]}

Craven, DE ^{[1
]}

Thornton, D ^{[1
]}

Tumilty, S ^{[1
]}

Nunes, D ^{[1
]}

机构：

[1] Boston Univ, Boston Med Ctr, Sch Med, Boston, MA 02118 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 36卷 / 01期

关键词：

D O I：

10.1086/344907

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

One hundred eighty human immunodeficiency virus (HIV)- and hepatitis C virus (HCV)-coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.

引用

页码：97 / 100

页数：4

共 10 条

[1] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].

Alter, MJ ;

Kruszon-Moran, D ;

Nainan, OV ;

McQuillan, GM ;

Gao, FX ;

Moyer, LA ;

Kaslow, RA ;

Margolis, HS .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562

[2]

[Anonymous], 1998, MMWR Recomm Rep, V47, P1

[3] Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].

Bica, I ;

McGovern, B ;

Dhar, R ;

Stone, D ;

McGowan, K ;

Scheib, R ;

Snydman, DR .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497

[4] HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C [J].

Di Martino, V ;

Thevenot, T ;

Boyer, N ;

Cazals-Hatem, D ;

Degott, C ;

Valla, D ;

Marcellin, P .

AIDS, 2002, 16 (03) :441-445

[5] The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study [J].

Di Martino, V ;

Rufat, P ;

Boyer, N ;

Renard, P ;

Degos, F ;

Martinot-Peignoux, M ;

Matheron, S ;

Le Moing, V ;

Vachon, F ;

Degott, C ;

Valla, D ;

Marcellin, P .

HEPATOLOGY, 2001, 34 (06) :1193-1199

[6] Surprisingly small effect of antiviral treatment in patients with hepatitis C [J].

Falck-Ytter, Y ;

Kale, H ;

Mullen, KD ;

Sarbah, SA ;

Sorescu, L ;

McCullough, AJ .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (04) :288-292

[7] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

[8]

MIR J, 1998, P 36 GEN M INF DIS S

[9] Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders [J].

Sauleda, S ;

Juárez, A ;

Esteban, JI ;

Altisent, C ;

Ruiz, I ;

Puig, L ;

Esteban, R ;

Guardia, J .

HEPATOLOGY, 2001, 34 (05) :1035-1040

[10] Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group [J].

Sherman, KE ;

Rouster, SD ;

Chung, RT ;

Rajicic, N .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :831-837

← 1 →